 Home > Medical News > Latest Medical News > Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza

Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza

 Last Update: 2021-05-10
 Source: Internet
 Author: User

Tags

company

osha medical

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

A few days ago, Eli Lilly announced that it would close its Dermira plant in Menlo Park, lay off 163 employees, and intend to sell the hyperhidrosis drug Qbrexza to Journey Medical.

Eli Lilly acquired Dermira, a dermatology company, in January 2020 for a total price of approximately US$1.

After a lapse of 16 months, Eli Lilly decided to abandon most of the investment portfolio obtained from this acquisition except Lebrikizumab, close the Dermira factory in Menlo Park, and sell the hyperhidrosis drug Qbrexza to Journey Medical.

The results of two important key trials show that Qbrexza can achieve a clinically significant improvement in sweat production.

Although Eli Lilly may lay off Dermira's employees, because Qbrexza is sold to Journey, Journey may also accept some of Dermira's former employees, but there is no exact news about how many employees will leave.

Although Dermira announced plans for plant closures and layoffs, recent news shows that the company's preclinical drugs have great potential.

In recent years, Eli Lilly has become more and more active in seeking solutions for skin diseases, especially atopic dermatitis.

Reference source: Lilly Closes Dermira's Menlo Park Facility, Cutting 163 Jobs in the Process

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.